Abstract Abstract #4111 Introduction
 In breast cancer (BC), adjuvant chemotherapy has become a standard therapy, resulting in prolonged survival. This goal might be affected by chemotherapy dose reductions and delays that are not uncommon features.
 The aim of this study was to assess relative dose intensity (RDI) reduction risk factors and define predictive factors.
 Methods
 Data regarding BC patients (pts) under anthracycline based-chemotherapy regimens was collected, retrospectively, from two Portuguese centres, between 1998 and 2007, and combined into a database of 783 individuals. Primary G-CSF prophylaxis was not planned. DIEP® (Dose Intensity Evaluation Programme) software was developed to allow calculation of RDI, and includes demographic data, clinical and treatment characteristics, chemotherapy dose modifications and delays, haematological toxicities and patterns of use of G-CSF.
 Univariate and multivariate analysis was performed to identify factors related to RDI ≤ 90% in these patients. A value of P < 0.05 was considered of statistical significance.
 Results
 Pts distribution according to chemotherapy: doxorubicin/cyclophosphamide (A60 C600) – 31,5%, 5-fluorouracil/epirubicin/cyclophosphamide (F500 E100 C500) – 19,2%, 5-fluorouracil/doxorubicin/cyclophosphamide (F500 A50 C500) – 49,3%. A RDI ≤ 90% was frequent across all chemotherapy regimens, but most common in pts receiving FEC (34,7%) and AC (23,5%) regimens.
 According to univariate analysis, factors related to reduction of RDI were: age ≥ 65 years (P = 0,006), node positive (P = 0,037), chemotherapy regimen (P < 0,001), number of pts with at least one G-CSF administration on secondary prophylaxis (P = 0,015), number of pts with at least one G-CSF administration due to neutropenia or febrile neutropenia (P < 0,001 ) and number of pts with at least one hospitalization due to febrile neutropenia (P < 0.001). In multivariate analysis, independent predictors of RDI ≤ 90% were: AC regimen (P = 0,008), FEC regimen (P = 0,002), age ≥ 65 years old (P = 0,018), node positive (P = 0,016) and at least one hospitalization due to febrile neutropenia (P < 0,001).
 Conclusion
 A considerable number of our BC pts, submitted to anthracycline based-chemotherapy, continue to experience RDI reductions. Most affected pts were more than 65 years old, or under FEC or AC regimens, or had node positive tumors. This data might help to identify a subgroup of BC pts that benefit from primary prophylaxis with G-CSF. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4111.
Read full abstract